Supplementary Appendix S1 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma Article Swipe

View

Srivandana Akshintala , R. Taylor Sundby , Donna Bernstein , John Glod , Rosandra N. Kaplan , Marielle E. Yohe , Andrea M. Gross , Joanne Derdak , Haiyan Lei , Alexander Pan , Eva Dombi , Isabel Palacio-Yance , Kailey R. Herrera , Markku Miettinen , Helen X. Chen , Seth M. Steinberg , Lee J. Helman , Leo Mascarenhas , Brigitte C. Widemann , Fariba Navid , Jack F. Shern , Christine M. Heske ·

YOU? · · 2024 · Open Access · · DOI: https://doi.org/10.1158/1078-0432.27032761

Supplemental Protocol Information. A: Study Eligibility; B: Dasatinib dosing nomogram; C: Dasatinib dose modifications

Related Topics

Proto-Oncogene Tyrosine-Protein Kinase Src

Concepts

Dasatinib Proto-oncogene tyrosine-protein kinase Src Insulin-like growth factor Cancer research Internal medicine Src family kinase Insulin receptor Chemistry Endocrinology Oncology Medicine Insulin Growth factor Receptor Insulin resistance Tyrosine kinase

Metadata

Type: preprint
Language: en
Landing Page: http://doi.org/10.1158/1078-0432.27032761
OA Status: gold
Related Works: 10
OpenAlex ID: https://openalex.org/W4402817329

All OpenAlex metadata

Raw OpenAlex JSON

OpenAlex ID: https://openalex.org/W4402817329

Canonical identifier for this work in OpenAlex
DOI: https://doi.org/10.1158/1078-0432.27032761

Digital Object Identifier
Title: Supplementary Appendix S1 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma

Work title
Type: preprint

OpenAlex work type
Language: en

Primary language
Publication year: 2024

Year of publication
Publication date: 2024-09-16

Full publication date if available
Authors: Srivandana Akshintala, R. Taylor Sundby, Donna Bernstein, John Glod, Rosandra N. Kaplan, Marielle E. Yohe, Andrea M. Gross, Joanne Derdak, Haiyan Lei, Alexander Pan, Eva Dombi, Isabel Palacio-Yance, Kailey R. Herrera, Markku Miettinen, Helen X. Chen, Seth M. Steinberg, Lee J. Helman, Leo Mascarenhas, Brigitte C. Widemann, Fariba Navid, Jack F. Shern, Christine M. Heske

List of authors in order
Landing page: https://doi.org/10.1158/1078-0432.27032761

Publisher landing page
Open access: Yes

Whether a free full text is available
OA status: gold

Open access status per OpenAlex
OA URL: https://doi.org/10.1158/1078-0432.27032761

Direct OA link when available
Concepts: Dasatinib, Proto-oncogene tyrosine-protein kinase Src, Insulin-like growth factor, Cancer research, Internal medicine, Src family kinase, Insulin receptor, Chemistry, Endocrinology, Oncology, Medicine, Insulin, Growth factor, Receptor, Insulin resistance, Tyrosine kinase

Top concepts (fields/topics) attached by OpenAlex
Cited by: 0

Total citation count in OpenAlex
Related works (count): 10

Other works algorithmically related by OpenAlex

Full payload

id	https://openalex.org/W4402817329
doi	https://doi.org/10.1158/1078-0432.27032761
ids.doi	https://doi.org/10.1158/1078-0432.27032761
ids.openalex	https://openalex.org/W4402817329
fwci	0.0
type	preprint
title	Supplementary Appendix S1 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma
biblio.issue
biblio.volume
biblio.last_page
biblio.first_page
topics[0].id	https://openalex.org/T10952
topics[0].field.id	https://openalex.org/fields/13
topics[0].field.display_name	Biochemistry, Genetics and Molecular Biology
topics[0].score	0.9660000205039978
topics[0].domain.id	https://openalex.org/domains/1
topics[0].domain.display_name	Life Sciences
topics[0].subfield.id	https://openalex.org/subfields/1312
topics[0].subfield.display_name	Molecular Biology
topics[0].display_name	PI3K/AKT/mTOR signaling in cancer
topics[1].id	https://openalex.org/T11215
topics[1].field.id	https://openalex.org/fields/27
topics[1].field.display_name	Medicine
topics[1].score	0.946399986743927
topics[1].domain.id	https://openalex.org/domains/4
topics[1].domain.display_name	Health Sciences
topics[1].subfield.id	https://openalex.org/subfields/2720
topics[1].subfield.display_name	Hematology
topics[1].display_name	Chronic Myeloid Leukemia Treatments
topics[2].id	https://openalex.org/T10253
topics[2].field.id	https://openalex.org/fields/27
topics[2].field.display_name	Medicine
topics[2].score	0.9277999997138977
topics[2].domain.id	https://openalex.org/domains/4
topics[2].domain.display_name	Health Sciences
topics[2].subfield.id	https://openalex.org/subfields/2740
topics[2].subfield.display_name	Pulmonary and Respiratory Medicine
topics[2].display_name	Sarcoma Diagnosis and Treatment
is_xpac	False
apc_list
apc_paid
concepts[0].id	https://openalex.org/C2779536868
concepts[0].level	4
concepts[0].score	0.8681734800338745
concepts[0].wikidata	https://www.wikidata.org/wiki/Q419940
concepts[0].display_name	Dasatinib
concepts[1].id	https://openalex.org/C108636557
concepts[1].level	3
concepts[1].score	0.6457669734954834
concepts[1].wikidata	https://www.wikidata.org/wiki/Q21109354
concepts[1].display_name	Proto-oncogene tyrosine-protein kinase Src
concepts[2].id	https://openalex.org/C2780689927
concepts[2].level	4
concepts[2].score	0.6332129240036011
concepts[2].wikidata	https://www.wikidata.org/wiki/Q24766801
concepts[2].display_name	Insulin-like growth factor
concepts[3].id	https://openalex.org/C502942594
concepts[3].level	1
concepts[3].score	0.5181195139884949
concepts[3].wikidata	https://www.wikidata.org/wiki/Q3421914
concepts[3].display_name	Cancer research
concepts[4].id	https://openalex.org/C126322002
concepts[4].level	1
concepts[4].score	0.4769933819770813
concepts[4].wikidata	https://www.wikidata.org/wiki/Q11180
concepts[4].display_name	Internal medicine
concepts[5].id	https://openalex.org/C2779976819
concepts[5].level	4
concepts[5].score	0.4539567828178406
concepts[5].wikidata	https://www.wikidata.org/wiki/Q7582406
concepts[5].display_name	Src family kinase
concepts[6].id	https://openalex.org/C112446052
concepts[6].level	4
concepts[6].score	0.44698524475097656
concepts[6].wikidata	https://www.wikidata.org/wiki/Q422579
concepts[6].display_name	Insulin receptor
concepts[7].id	https://openalex.org/C185592680
concepts[7].level	0
concepts[7].score	0.397394061088562
concepts[7].wikidata	https://www.wikidata.org/wiki/Q2329
concepts[7].display_name	Chemistry
concepts[8].id	https://openalex.org/C134018914
concepts[8].level	1
concepts[8].score	0.3911992311477661
concepts[8].wikidata	https://www.wikidata.org/wiki/Q162606
concepts[8].display_name	Endocrinology
concepts[9].id	https://openalex.org/C143998085
concepts[9].level	1
concepts[9].score	0.36286887526512146
concepts[9].wikidata	https://www.wikidata.org/wiki/Q162555
concepts[9].display_name	Oncology
concepts[10].id	https://openalex.org/C71924100
concepts[10].level	0
concepts[10].score	0.335470974445343
concepts[10].wikidata	https://www.wikidata.org/wiki/Q11190
concepts[10].display_name	Medicine
concepts[11].id	https://openalex.org/C2779306644
concepts[11].level	2
concepts[11].score	0.3177917003631592
concepts[11].wikidata	https://www.wikidata.org/wiki/Q2002370
concepts[11].display_name	Insulin
concepts[12].id	https://openalex.org/C2775960820
concepts[12].level	3
concepts[12].score	0.31220945715904236
concepts[12].wikidata	https://www.wikidata.org/wiki/Q408378
concepts[12].display_name	Growth factor
concepts[13].id	https://openalex.org/C170493617
concepts[13].level	2
concepts[13].score	0.2753487229347229
concepts[13].wikidata	https://www.wikidata.org/wiki/Q208467
concepts[13].display_name	Receptor
concepts[14].id	https://openalex.org/C2777391703
concepts[14].level	3
concepts[14].score	0.15514281392097473
concepts[14].wikidata	https://www.wikidata.org/wiki/Q1053470
concepts[14].display_name	Insulin resistance
concepts[15].id	https://openalex.org/C42362537
concepts[15].level	3
concepts[15].score	0.12056219577789307
concepts[15].wikidata	https://www.wikidata.org/wiki/Q87099740
concepts[15].display_name	Tyrosine kinase
keywords[0].id	https://openalex.org/keywords/dasatinib
keywords[0].score	0.8681734800338745
keywords[0].display_name	Dasatinib
keywords[1].id	https://openalex.org/keywords/proto-oncogene-tyrosine-protein-kinase-src
keywords[1].score	0.6457669734954834
keywords[1].display_name	Proto-oncogene tyrosine-protein kinase Src
keywords[2].id	https://openalex.org/keywords/insulin-like-growth-factor
keywords[2].score	0.6332129240036011
keywords[2].display_name	Insulin-like growth factor
keywords[3].id	https://openalex.org/keywords/cancer-research
keywords[3].score	0.5181195139884949
keywords[3].display_name	Cancer research
keywords[4].id	https://openalex.org/keywords/internal-medicine
keywords[4].score	0.4769933819770813
keywords[4].display_name	Internal medicine
keywords[5].id	https://openalex.org/keywords/src-family-kinase
keywords[5].score	0.4539567828178406
keywords[5].display_name	Src family kinase
keywords[6].id	https://openalex.org/keywords/insulin-receptor
keywords[6].score	0.44698524475097656
keywords[6].display_name	Insulin receptor
keywords[7].id	https://openalex.org/keywords/chemistry
keywords[7].score	0.397394061088562
keywords[7].display_name	Chemistry
keywords[8].id	https://openalex.org/keywords/endocrinology
keywords[8].score	0.3911992311477661
keywords[8].display_name	Endocrinology
keywords[9].id	https://openalex.org/keywords/oncology
keywords[9].score	0.36286887526512146
keywords[9].display_name	Oncology
keywords[10].id	https://openalex.org/keywords/medicine
keywords[10].score	0.335470974445343
keywords[10].display_name	Medicine
keywords[11].id	https://openalex.org/keywords/insulin
keywords[11].score	0.3177917003631592
keywords[11].display_name	Insulin
keywords[12].id	https://openalex.org/keywords/growth-factor
keywords[12].score	0.31220945715904236
keywords[12].display_name	Growth factor
keywords[13].id	https://openalex.org/keywords/receptor
keywords[13].score	0.2753487229347229
keywords[13].display_name	Receptor
keywords[14].id	https://openalex.org/keywords/insulin-resistance
keywords[14].score	0.15514281392097473
keywords[14].display_name	Insulin resistance
keywords[15].id	https://openalex.org/keywords/tyrosine-kinase
keywords[15].score	0.12056219577789307
keywords[15].display_name	Tyrosine kinase
language	en
locations[0].id	doi:10.1158/1078-0432.27032761
locations[0].is_oa	True
locations[0].source
locations[0].license	cc-by
locations[0].pdf_url
locations[0].version	acceptedVersion
locations[0].raw_type	posted-content
locations[0].license_id	https://openalex.org/licenses/cc-by
locations[0].is_accepted	True
locations[0].is_published	False
locations[0].raw_source_name
locations[0].landing_page_url	http://doi.org/10.1158/1078-0432.27032761
indexed_in	crossref
authorships[0].author.id	https://openalex.org/A5028204560
authorships[0].author.orcid	https://orcid.org/0000-0002-3478-9893
authorships[0].author.display_name	Srivandana Akshintala
authorships[0].author_position	first
authorships[0].raw_author_name	Srivandana Akshintala
authorships[0].is_corresponding	False
authorships[1].author.id	https://openalex.org/A5034958185
authorships[1].author.orcid	https://orcid.org/0000-0001-8485-0026
authorships[1].author.display_name	R. Taylor Sundby
authorships[1].author_position	middle
authorships[1].raw_author_name	R. Taylor. Sundby
authorships[1].is_corresponding	False
authorships[2].author.id	https://openalex.org/A5052568161
authorships[2].author.orcid
authorships[2].author.display_name	Donna Bernstein
authorships[2].author_position	middle
authorships[2].raw_author_name	Donna Bernstein
authorships[2].is_corresponding	False
authorships[3].author.id	https://openalex.org/A5008972260
authorships[3].author.orcid	https://orcid.org/0000-0002-3071-7876
authorships[3].author.display_name	John Glod
authorships[3].author_position	middle
authorships[3].raw_author_name	John W. Glod
authorships[3].is_corresponding	False
authorships[4].author.id	https://openalex.org/A5021388942
authorships[4].author.orcid	https://orcid.org/0000-0002-8580-0001
authorships[4].author.display_name	Rosandra N. Kaplan
authorships[4].author_position	middle
authorships[4].raw_author_name	Rosandra N. Kaplan
authorships[4].is_corresponding	False
authorships[5].author.id	https://openalex.org/A5023309436
authorships[5].author.orcid	https://orcid.org/0000-0001-5356-9426
authorships[5].author.display_name	Marielle E. Yohe
authorships[5].author_position	middle
authorships[5].raw_author_name	Marielle E. Yohe
authorships[5].is_corresponding	False
authorships[6].author.id	https://openalex.org/A5013034227
authorships[6].author.orcid	https://orcid.org/0000-0003-1646-4531
authorships[6].author.display_name	Andrea M. Gross
authorships[6].author_position	middle
authorships[6].raw_author_name	Andrea M. Gross
authorships[6].is_corresponding	False
authorships[7].author.id	https://openalex.org/A5065281591
authorships[7].author.orcid	https://orcid.org/0009-0008-1560-9894
authorships[7].author.display_name	Joanne Derdak
authorships[7].author_position	middle
authorships[7].raw_author_name	Joanne Derdak
authorships[7].is_corresponding	False
authorships[8].author.id	https://openalex.org/A5017446252
authorships[8].author.orcid	https://orcid.org/0000-0002-9955-6281
authorships[8].author.display_name	Haiyan Lei
authorships[8].author_position	middle
authorships[8].raw_author_name	Haiyan Lei
authorships[8].is_corresponding	False
authorships[9].author.id	https://openalex.org/A5042084582
authorships[9].author.orcid	https://orcid.org/0000-0002-9744-4155
authorships[9].author.display_name	Alexander Pan
authorships[9].author_position	middle
authorships[9].raw_author_name	Alexander Pan
authorships[9].is_corresponding	False
authorships[10].author.id	https://openalex.org/A5055973779
authorships[10].author.orcid	https://orcid.org/0000-0002-5323-6995
authorships[10].author.display_name	Eva Dombi
authorships[10].author_position	middle
authorships[10].raw_author_name	Eva Dombi
authorships[10].is_corresponding	False
authorships[11].author.id	https://openalex.org/A5026579984
authorships[11].author.orcid	https://orcid.org/0009-0003-3140-3881
authorships[11].author.display_name	Isabel Palacio-Yance
authorships[11].author_position	middle
authorships[11].raw_author_name	Isabel Palacio-Yance
authorships[11].is_corresponding	False
authorships[12].author.id	https://openalex.org/A5030762553
authorships[12].author.orcid	https://orcid.org/0009-0003-9552-6784
authorships[12].author.display_name	Kailey R. Herrera
authorships[12].author_position	middle
authorships[12].raw_author_name	Kailey R. Herrera
authorships[12].is_corresponding	False
authorships[13].author.id	https://openalex.org/A5024934444
authorships[13].author.orcid	https://orcid.org/0000-0002-3282-8107
authorships[13].author.display_name	Markku Miettinen
authorships[13].author_position	middle
authorships[13].raw_author_name	Markku M. Miettinen
authorships[13].is_corresponding	False
authorships[14].author.id	https://openalex.org/A5052180490
authorships[14].author.orcid	https://orcid.org/0000-0001-9959-8417
authorships[14].author.display_name	Helen X. Chen
authorships[14].author_position	middle
authorships[14].raw_author_name	Helen X. Chen
authorships[14].is_corresponding	False
authorships[15].author.id	https://openalex.org/A5044239219
authorships[15].author.orcid	https://orcid.org/0000-0002-8280-551X
authorships[15].author.display_name	Seth M. Steinberg
authorships[15].author_position	middle
authorships[15].raw_author_name	Seth M. Steinberg
authorships[15].is_corresponding	False
authorships[16].author.id	https://openalex.org/A5066585382
authorships[16].author.orcid	https://orcid.org/0000-0001-9553-4475
authorships[16].author.display_name	Lee J. Helman
authorships[16].author_position	middle
authorships[16].raw_author_name	Lee J. Helman
authorships[16].is_corresponding	False
authorships[17].author.id	https://openalex.org/A5071801742
authorships[17].author.orcid	https://orcid.org/0000-0001-7790-0777
authorships[17].author.display_name	Leo Mascarenhas
authorships[17].author_position	middle
authorships[17].raw_author_name	Leo Mascarenhas
authorships[17].is_corresponding	False
authorships[18].author.id	https://openalex.org/A5071679104
authorships[18].author.orcid	https://orcid.org/0000-0002-9198-7175
authorships[18].author.display_name	Brigitte C. Widemann
authorships[18].author_position	middle
authorships[18].raw_author_name	Brigitte C. Widemann
authorships[18].is_corresponding	False
authorships[19].author.id	https://openalex.org/A5045180889
authorships[19].author.orcid	https://orcid.org/0000-0002-7916-6382
authorships[19].author.display_name	Fariba Navid
authorships[19].author_position	middle
authorships[19].raw_author_name	Fariba Navid
authorships[19].is_corresponding	False
authorships[20].author.id	https://openalex.org/A5003760804
authorships[20].author.orcid	https://orcid.org/0000-0001-5579-7625
authorships[20].author.display_name	Jack F. Shern
authorships[20].author_position	middle
authorships[20].raw_author_name	Jack F. Shern
authorships[20].is_corresponding	False
authorships[21].author.id	https://openalex.org/A5018153866
authorships[21].author.orcid	https://orcid.org/0000-0003-0956-6249
authorships[21].author.display_name	Christine M. Heske
authorships[21].author_position	last
authorships[21].raw_author_name	Christine M. Heske
authorships[21].is_corresponding	False
has_content.pdf	False
has_content.grobid_xml	False
is_paratext	False
open_access.is_oa	True
open_access.oa_url	http://doi.org/10.1158/1078-0432.27032761
open_access.oa_status	gold
open_access.any_repository_has_fulltext	False
created_date	2025-10-10T00:00:00
display_name	Supplementary Appendix S1 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma
has_fulltext	False
is_retracted	False
updated_date	2025-11-06T03:46:38.306776
primary_topic.id	https://openalex.org/T10952
primary_topic.field.id	https://openalex.org/fields/13
primary_topic.field.display_name	Biochemistry, Genetics and Molecular Biology
primary_topic.score	0.9660000205039978
primary_topic.domain.id	https://openalex.org/domains/1
primary_topic.domain.display_name	Life Sciences
primary_topic.subfield.id	https://openalex.org/subfields/1312
primary_topic.subfield.display_name	Molecular Biology
primary_topic.display_name	PI3K/AKT/mTOR signaling in cancer
related_works	https://openalex.org/W2143807312, https://openalex.org/W2143974518, https://openalex.org/W2037478956, https://openalex.org/W4361873059, https://openalex.org/W4362420547, https://openalex.org/W1991541715, https://openalex.org/W2145023069, https://openalex.org/W2737698771, https://openalex.org/W2033495545, https://openalex.org/W1560827802
cited_by_count	0
locations_count	1
best_oa_location.id	doi:10.1158/1078-0432.27032761
best_oa_location.is_oa	True
best_oa_location.source
best_oa_location.license	cc-by
best_oa_location.pdf_url
best_oa_location.version	acceptedVersion
best_oa_location.raw_type	posted-content
best_oa_location.license_id	https://openalex.org/licenses/cc-by
best_oa_location.is_accepted	True
best_oa_location.is_published	False
best_oa_location.raw_source_name
best_oa_location.landing_page_url	http://doi.org/10.1158/1078-0432.27032761
primary_location.id	doi:10.1158/1078-0432.27032761
primary_location.is_oa	True
primary_location.source
primary_location.license	cc-by
primary_location.pdf_url
primary_location.version	acceptedVersion
primary_location.raw_type	posted-content
primary_location.license_id	https://openalex.org/licenses/cc-by
primary_location.is_accepted	True
primary_location.is_published	False
primary_location.raw_source_name
primary_location.landing_page_url	http://doi.org/10.1158/1078-0432.27032761
publication_date	2024-09-16
publication_year	2024
referenced_works_count	0
abstract_inverted_index.A:	3
abstract_inverted_index.B:	6
abstract_inverted_index.C:	10
abstract_inverted_index.dose	12
abstract_inverted_index.Study	4
abstract_inverted_index.dosing	8
abstract_inverted_index.Protocol	1
abstract_inverted_index.Dasatinib	7, 11
abstract_inverted_index.nomogram;	9
abstract_inverted_index.Eligibility;	5
abstract_inverted_index.Information.	2
abstract_inverted_index.<p>Supplemental	0
abstract_inverted_index.modifications</p>	13
cited_by_percentile_year
countries_distinct_count	0
institutions_distinct_count	22
citation_normalized_percentile.value	0.18543439
citation_normalized_percentile.is_in_top_1_percent	False
citation_normalized_percentile.is_in_top_10_percent	False